ProSciento’s Board members have been at the forefront of metabolic research and drug development, both in industry and academia, and have held leadership positions at more than 25 life science companies.
Board of Directors
Marcus Hompesch, M.D.
Chief Executive Officer and Chairman of the Board at ProSciento, Inc.
John Amatruda, M.D.
Pharmaceutical Research Executive and former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories
Linda Morrow, M.D.
Former Chief Medical Officer at ProSciento, Inc.
Dan Bradbury
Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO
Jerrold Olefsky, M.D.
Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine
Anthony M. Stiegler
Partner at Cooley LLP and Senior Director, Operations, Policy & Regulatory, at The Salk Institute, Harnessing Plants Initiative